The Organ Preservation Solutions Market is growing at a steady pace because global transplant waiting lists keep lengthening while ischemia-related graft loss remains a critical clinical constraint. In 2025, deceased donors accounted for the largest share of transplantable organs, and the Deceased Organ Donation Market continues to drive sales of cold storage fluids, hypothermic machines, and logistically integrated preservation devices. With a forecast compound annual growth rate (CAGR) of 7.5%, the total market will expand from USD 291.2 million to roughly USD 519.5 million by 2033.

Transplant programs are shifting from retrospective discard management to proactive viability assessment. This shift is most visible in kidney and liver transplantation, where prolonged cold ischemic time directly correlates with delayed graft function and graft survival. Health systems that deploy single-pass machine perfusion or controlled oxygenated rewarming are reporting fewer organ discards and shorter intensive care unit stays, creating a strong value proposition for preservation budgets.

On the supply side, a concentrated group of device manufacturers and solution formulators must maintain continuous temperature stability across multiple geographies. The economic moat is not manufacturing scale; it is regulatory clearance and clinical evidence required to convince transplant surgeons. Several European vendors are using trial data from high-volume centers to enter North American markets, while U.S.-based innovators are expanding through hospital group purchasing contracts.

Macro drivers include an aging donor pool, increased adoption of donation after circulatory death protocols, and rising public investment in transplant infrastructure. The strategic direction for vendors is clear: digitize transport, add perfusion biomarkers, and align reimbursement codes with demonstrated graft survival improvements.

The Deceased Organ Donation Market is the largest demand pocket in the preservation industry. Organs from deceased donors make up around 70% of recovered hearts, livers, and kidneys in the United States, and donation after circulatory death now accounts for over 30% of deceased donor organ recovery in several European countries. Because deceased donors require coordinated surgical recovery teams, preservation periods are longer and more variable than living donation procedures. That variability increases demand for oxygenated perfusion, controlled cold storage, and real-time pressure monitoring rather than passive ice immersion.

In 2025, the deceased organ donation type segment represents close to 65% of the type-based market value. Deceased donor procedures generate higher average selling prices for preservation solutions and single-use disposable kits because surgical teams often need extended preservation windows for organ allocation and cross-country transport. The segment is also gaining from policies that prioritize the efficient use of marginal or extended-criteria donor organs. These organs require more sophisticated viability assessment, giving an advantage to platforms that integrate perfusion pressure, flow resistance, and lactate clearance measurements.

The Living Organ Donation Market grows at a slower estimated rate of 5.9% during the forecast period. Living donor nephrectomy and living donor liver transplant create short cold ischemia windows, usually under four hours, so low-cost static storage remains common. However, the Living Organ Donation Market still contributes steady procurement of sterile preservation solutions and transport containers. The clinical priority in this segment is safety and traceability rather than prolonged organ support, which limits expansion of high-price perfusion hardware.

The Organ Preservation Hospital Market is the largest end-user segment because transplant programs are hospital-centered. Hospitals account for more than 70% of preservation procurement budgets, while organ banks and procurement organizations purchase devices but often operate under hospital service agreements. The Organ Banking Services Market is evolving as organ procurement organizations add perfusion and viability testing as covered services, but in most jurisdictions organ storage is not run as an independent profit center.

Hospitals prefer vendors that offer installation, training, and 24-hour replacement logistics. The hospital segment is partly shifting from capital ownership to managed service contracts in which the preservation vendor installs a perfusion machine and charges per perfused organ. This model lowers upfront costs, improves utilization reporting, and makes advanced perfusion accessible to smaller transplant centers.

Transplant volume growth remains the anchor demand driver. In the United States alone, more than 40,000 organ transplants are now performed annually, while the number of active waitlist candidates continues to exceed 100,000. This sustained gap creates pressure on procurement organizations to accept organs from older donors and donation after circulatory death, both of which extend preservation requirements. As a result, procurement teams are investing in portable preservation devices that reduce cold ischemic injury and support more remote organ allocation.

Clinical evidence is the second major growth catalyst. Published transplant data link machine perfusion with reduced delayed graft function in kidneys, lower biliary complications in livers, and shorter ventilator time after lung transplantation. Payers and hospital executives increasingly treat preservation technology not as an optional add-on but as a cost-saving measure tied to transplant outcomes.

Despite these drivers, high upfront capital still hampers adoption. The Static Cold Storage Market remains the default in low-resource settings because a static cooler is relatively inexpensive, while a portable hypothermic machine can cost between USD 25,000 and USD 300,000. The Cold Storage Preservation Market keeps its position through cheaper reimbursement and simpler training, but static storage is associated with measurable graft injury in extended-criteria donor organs. This creates a widening gap: high-volume transplant centers can justify advanced perfusion economics, while smaller programs remain cost-sensitive. The Machine Perfusion Market is growing at more than 11% annually, yet it still only accounts for a minority of recovered organs globally.

• 21st Century Medicine: develops low-temperature organ preservation technology and specializes in vitrification and supercooling research, offering long-term preservation alternatives for clinical and research settings.
• Accord Healthcare Ltd.: supplies generic injectable pharmaceuticals and preservation-related solutions to hospital and transplant pharmacy channels.
• BioLife Solutions Inc.: commercializes serum-free and protein-free preservation media for cells and tissues; its biopreservation media portfolio supports transplant ancillary markets.
• Bridge to Life Ltd.: markets organ preservation solutions and disposable cold storage products with an established presence in kidney and liver preservation workflows.
• Carnamedica: provides organ transport bags, sterile packaging, and cold chain consumables used during deceased organ donation procedures.
• Dr. Franz Koehler Chemie GmbH: manufacturer of Custodiol HTK solution, widely used for cardioplegia and organ preservation; its distribution network is a key competitive asset.
• EBERS MEDICAL TECHNOLOGY SL: focuses on hypothermic oxygenated perfusion equipment and disposable perfusion sets for liver preservation.
• Global Transplant Solutions: supplies organ storage and transport consumables to procurement organizations in North America and Europe.
• Organ Recovery Systems Inc.: best known for the LifePort Kidney Transporter, with broad clinical adoption and recurrent service contract revenue.
• OrganOx Ltd.: markets the OrganOx metra normothermic liver perfusion system and has built a strong evidence base for reducing liver graft discard.
• Paragonix Technologies Inc.: develops SherpaPak controlled-temperature cardiac and lung transport systems and continues to expand registry studies supporting lower primary graft dysfunction.
• Preservation Solution Inc.: a niche formulator of organ preservation solution supporting kidney and liver procurement protocols.
• Revive Organtech Inc.: an emerging developer of oxygenated perfusion technologies for abdominal organs.
• SALF SpA: European supplier of medical devices and packaging used for organ transport and cold chain management.
• TransMedics Inc.: makes the Organ Care System, a portable warm blood perfusion platform for heart, lung, and liver transplantation.
• TX Innovations: provides tissue preservation and organ transport platforms, mainly serving North American transplant centers.
• Waters Medical Systems LLC: supplies portable cold storage and temperature-monitored transport equipment for transplant logistics.
• XVIVO Perfusion AB: supplies the XVIVO Perfusion System and corresponding preservation solutions for lung and kidney machine perfusion.

• January 2023: The U.S. Health Resources and Services Administration adjusted organ procurement organization performance measures, placing greater emphasis on donor hospital response times and preservation logistics efficiency.
• August 2023: Paragonix Technologies expanded its controlled-temperature preservation portfolio into lung transport, increasing competition in the advanced thoracic preservation segment.
• February 2024: XVIVO Perfusion AB reported registry-level results demonstrating lower kidney discard rates when controlled oxygenated rewarming was used before transplantation.
• October 2024: TransMedics expanded the use of its Organ Care System liver transport protocol to include selected donation-after-circulatory-death livers in U.S. procurement service areas.
• December 2024: OrganOx and hospital partners in the UK completed rollouts of continuous perfusion data transmission to transplant coordination centers, making remote monitoring a standard feature for high-risk liver offers.

North America remains the largest regional market, with an estimated 2025 value of USD 110.7 million, representing a 38% share. Regional growth is stable at approximately 7.0% because device penetration is already high and replacement procurement cycles are predictable. The United States drives demand through well-funded organ procurement organizations and a strong FDA regulatory pathway for new preservation devices.

Europe represents about USD 81.5 million of the global market in 2025. Germany, the UK, Spain, and Italy are the leading centers because of their high deceased donation rates and mature transplant registries. European procurement organizations are early adopters of hypothermic oxygenated perfusion and the regulatory environment supports post-market quality registries. At 7.4% CAGR, Europe remains slightly above the global average, helped by cross-border organ exchange agreements and EDQM quality standards.

Asia-Pacific is the fastest-growing regional market, at about 9.6% CAGR, with an estimated 2025 value of USD 67.0 million. China is investing in deceased donor transplant infrastructure, while Japan and South Korea are building advanced machine perfusion research programs. India is the largest demand growth engine for kidney preservation because of high liver and kidney disease prevalence and expanding transplant capacity in private hospitals.

South America and the Middle East and Africa are smaller markets, together accounting for approximately USD 32.1 million in 2025. Brazil and Turkey lead due to active transplant networks and higher numbers of deceased donor procedures relative to nearby countries. These regions are likely to adopt cheaper static storage devices first, with machine perfusion gradually entering large public transplant referral centers.

Vendors in the Organ Preservation Chemicals Market compete through low-temperature stability, additive purity, and compatibility with FDA and EU regulatory expectations. Essential raw materials include histidine, tryptophan, lactobionic acid, glutathione, adenosine, allopurinol, raffinose, and hydroxyethyl starch. University of Wisconsin solution and histidine-tryptophan-ketoglutarate solution remain the most widely used preservation fluids globally.

Raw material pricing is tightening because many of these compounds require pharmaceutical-grade purity and cold-chain handling. In 2024, European and North American manufacturers reported average input cost inflation of 6 to 8% for synthetic preservation solution components. Lactobionic acid, in particular, is supplied by a small number of specialty chemical manufacturers, creating sourcing risk for formulators.

The physical supply chain also depends on temperature-controlled containers, dry ice, gel packs, and continuous temperature sensors. A single logistics failure can require a transplant to be postponed, so procurement organizations often keep duplicate inventory at each hospital. This practice increases working capital needs but reduces discard risk and is now a standard expectation in high-volume organ transport.

In the United States, organ preservation devices are regulated by FDA's Center for Devices and Radiological Health, typically through 510(k) clearance or de novo pathways. Organ procurement organizations must follow performance standards set by the Organ Procurement and Transplantation Network and the Health Resources and Services Administration. Recent policy shifts focus on reducing geographic disparities in organ allocation, which directly increases the need for transportable preservation systems.

Europe applies the Medical Device Regulation 2017/745 to preservation hardware and pharmaceutical quality standards to preservation solutions. EDQM has developed guidelines for organ preservation quality and traceability, and several European countries now mandate capture of cold ischemia time in transplant registries. These requirements are creating a compliance advantage for vendors with integrated digital temperature and pressure logging.

In Asia-Pacific, regulatory paths vary by country. China has implemented a national voluntary organ donor system and requires approved storage and transport suppliers for hospital transplant programs. Japan and South Korea have begun harmonizing their medical device review pathways with international standards, making it easier for global perfusion vendors to enter. India is establishing more rigorous cold chain and traceability rules, but enforcement remains inconsistent outside major urban transplant centers.

• 1. Organ Preservation Market Is Segmented By Type
  • 1.1. Living organ donation
  • 1.2. Deceased organ donation
• 2. End-User
  • 2.1. Hospitals
  • 2.2. clinics
  • 2.3. Organ banks
  • 2.4. Others

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific